-- 据彭博社周四报道，美国食品药品监督管理局（FDA）肿瘤药物咨询委员会否决了阿斯利康（AZN）用于治疗乳腺癌的候选药物卡美司群（Camizestrant）的疗效。 彭博社称，六名委员会成员投票反对该药物，原因是他们对试验设计及其在临床应用中的潜在影响存在分歧。 根据一份简报文件，该药物试验达到了无进展生存期（PFS）的主要终点以及无进展生存期2（PFS2）终点，但FDA认为PFS2不适合作为监管决策的终点。 （市场动态新闻来源于与全球市场专业人士的对话。这些信息据信来自可靠来源，但可能包含传闻和推测。准确性无法保证。）
Price: $189.60, Change: $+4.40, Percent Change: +2.37%
(Updates with Solventum's response to a request for comment.)Solventum (SOLV) is being significantly "under-managed" following its spin-out from 3M (MMM) and must take steps to restore its performance, Trian Fund Management said Thursday in an open letter to Solventum's board.Trian, which owns nearly 5% of Solventum, said the company should right-size overhead costs, simplify its portfolio, and improve capital allocation."The Solventum Board and management team have engaged constructively and continuously with Trian since it became a shareholder and fully share the objective of maximizing shareholder value," a Solventum spokesperson toldvia email.Price: $67.60, Change: $+1.11, Percent Change: +1.67%
3:00 Thursday vs 3:00 Wednesday2yr 99-23 vs 99-21; 3.881% vs 3.926%5yr 99-11 vs 99-09; 4.019% vs 4.056%10yr 97-29 vs 97-24; 4.388% vs 4.409%30yr 96-11 vs 96-13; 4.985% vs 4.979%2/10 50.435 bps vs 48.031 bps5/30 96.315 bps vs 92.231 bps
(Updates with the latest stock price movement in the headline and the first paragraph.)Sprouts Farmers Market (SFM) shares rose 18% on Thursday, a day after the company reported higher-than-expected Q1 results.The company reported Q1 net income late Wednesday of $1.71 per diluted share, down from $1.81 a year earlier.Analysts polled by FactSet expected $1.68.Net sales for the three months ended March 29 rose to $2.33 billion from $2.24 billion a year earlier.Analysts surveyed by FactSet expected $2.32 billion.The company said it expects Q2 EPS of $1.32 to $1.36. Analysts expect $1.35.The company now expects 2026 EPS of $5.32 to $5.48, compared with its prior guidance of $5.28 to $5.44. Analysts expect $5.54.Price: $83.76, Change: $+12.63, Percent Change: +17.76%